Infographic | November 15, 2021

Small Molecule Sterile Injectable Outsourcing Volume

Source: ISR Reports

In Q2 2021, ISR asked 57 respondents how many small molecule sterile injectable products they have on the market, the proportion of sterile injectable manufacturing that is outsourced and the number of CDMOs they use to complete the work. On average, respondents have 3.4 marketed biologic products, of which 67% of drug product manufacturing is outsourced and use an average of 3.3 CDMOs.  To learn how these proportions are predicted to change in the next five years, follow the link to the Sterile Injectable Market Outlook report preview. 


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online